undefined

Jonathan Wosen

STAT biotech reporter, providing insights into NIH funding cuts and their impact on biomedical innovation.

Top 3 podcasts with Jonathan Wosen

Ranked by the Snipd community
undefined
12 snips
Feb 13, 2025 • 27min

341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers

Biotech reporter Jonathan Wosen discusses the NIH's significant funding cuts and the looming brain drain that could push young researchers overseas. Health tech reporter Brittany Trang dives into the skeptical reactions towards AI drug developers like Absci and Generate:Biomedicines, who assert they can create drugs from scratch. The conversation sheds light on the potential impact of reduced NIH support on U.S. biomedical innovation and the challenges of relying on AI in drug discovery.
undefined
Sep 26, 2024 • 32min

324: Genentech's cancer pivot, Pfizer's sickle cell withdrawal, and a new schizophrenia drug

Jonathan Wosen, a seasoned colleague in oncology research, shares insights on the latest shifts in the life sciences. The conversation highlights Genentech's decision to close its cancer immunology division and the reaction from the biotech community. Wosen also discusses Pfizer’s withdrawal of its sickle cell treatment and the implications for future drug approvals. Additionally, they explore the promising prospects of a new schizophrenia drug set to be approved, emphasizing the urgent need for innovative therapies in mental health.
undefined
Aug 29, 2024 • 38min

320: Jim Wilson's next venture, a surprise startup shutdown, & Lilly's Zepbound strategy

In this engaging discussion, gene therapy pioneer Jim Wilson, known for his groundbreaking work at the University of Pennsylvania, shares insights on his recent departure and future plans. Joining him is Jonathan Wosen, a biotech reporter, who sheds light on the surprising closure of a gene editing company and the challenges facing the industry. They explore Eli Lilly's new pricing strategy for its obesity drug, Zepbound, and the shift toward direct-to-consumer sales. The conversation captures the dynamic, often unpredictable nature of biotech today.